The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria?

Biomed Res Int. 2014:2014:687608. doi: 10.1155/2014/687608. Epub 2014 Aug 14.

Abstract

Patients with clinical suspicion of large-vessel vasculitis (LVV) may present with nonspecific signs and symptoms and increased inflammatory parameters and may remain without diagnosis after routine diagnostic procedures. Both the nonspecificity of the radiopharmaceutical (18)F-FDG and the synergy of integrating functional and anatomical images with PET/CT offer substantial benefit in the diagnostic work-up of patients with clinical suspicion for LVV. A negative temporal artery biopsy, an ultrasonography without an arterial halo, or a MRI without aortic wall thickening or oedema do not exclude the presence of LVV and should therefore not exclude the use of (18)F-FDG PET/CT when LVV is clinically suspected. This overview further discusses the notion that there is substantial underdiagnosis of LVV. Late diagnosis of LVV may lead to surgery or angioplasty in occlusive forms and is often accompanied by serious aortic complications and a fatal outcome. In contrast to the American College of Rheumatology 1990 criteria for vasculitis, based on late LVV effects like arterial stenosis and/or occlusion, (18)F-FDG PET/CT sheds new light on the classification of giant cell arteritis (GCA) and Takayasu arteritis (TA). The combination of these observations makes the role of (18)F-FDG PET/CT in the assessment of patients suspected for having LVV promising.

Publication types

  • Review

MeSH terms

  • Cardiology / standards*
  • Fluorodeoxyglucose F18*
  • Humans
  • Multimodal Imaging / standards*
  • Positron-Emission Tomography / standards*
  • Practice Guidelines as Topic
  • Radiology / standards*
  • Radiopharmaceuticals
  • Tomography, X-Ray Computed / methods*
  • United States
  • Vasculitis / diagnosis*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18